Diagnosis and treatment of disseminated intravascular coagulation: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET)

Nisio, Marcello Di; Baudo, F.; Cosmi, Benilde; D’Angelo, Armando; Gasperi, Andrea De; Malato, Alessandra; Schiavoni, M.; Squizzato, Alessandro

doi:10.1016/j.thromres.2011.08.028

Cited by 123 publications

(119 citation statements)

References 45 publications

Supporting

Mentioning

108

Contrasting

Unclassified

Order By: Relevance

“…In contrast to the guidelines for the management of DIC in other countries, the Japanese Society of Thrombosis and Hemostasis recommends the use of antithrombin for DIC treatment and the Japanese Ministry of Health, Labour and Welfare permits the use of antithrombin as a DIC treatment drug [31][32][33]. The JAAM DIC Study Group was apprehensive about the decision of the ethics committees of the participating hospitals; therefore, the use of gabexate mesilate was permitted when the ethics committees required some interventions for the control group.…”

Section: Discussionmentioning

confidence: 99%

A Randomized, Controlled, Multicenter Trial of the Effects of Antithrombin on Disseminated Intravascular Coagulation in Patients With Sepsis

Gando

Saitoh²,

Ishikura³

et al. 2013

Chest

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

A Randomized, Controlled, Multicenter Trial of the Effects of Antithrombin on Disseminated Intravascular Coagulation in Patients With Sepsis

Gando

Saitoh²,

Ishikura³

et al. 2013

Chest

View full text Add to dashboard Cite

“…46 Similar scoring systems and diagnostic guidance have been developed and extensively evaluated in Japan, Italy and the United Kingdom. [47][48][49] The major difference between the international and Japanese scoring systems seems a slightly higher sensitivity of the Japanese algorithm, although this may be due to different patient populations as Japanese series typically include relatively large numbers of patients with haematological malignancies. In our patient the platelet count (1 point), prolongation of the PT (1 point) and strongly increased D-dimer (3 points) leads to a score of 5 points, compatible with a diagnosis of DIC.…”

Section: Comments About Patientmentioning

confidence: 99%

How I treat disseminated intravascular coagulation

Levi

Scully

2018

Blood

203

191

View full text Add to dashboard Cite

Disseminated intravascular coagulation (DIC) is a condition characterised by systemic activation of coagulation, potentially leading to thrombotic obstruction of small and midsize vessels, thereby contributing to organ dysfunction. At the same time, ongoing consumption of platelets and coagulation proteins results in thrombocytopenia and low concentrations of clotting factors, which may cause profuse hemorrhagic complications. DIC is always secondary to an underlying condition, such as severe infections, solid or hematologic malignancies, trauma, or obstetric calamities. A reliable diagnosis of DIC can be made through simple scoring algorithms based on readily available routine hemostatic parameters. The cornerstone of supportive treatment of this coagulopathy is management of the underlying condition.

show abstract

“…For example, Italian or Japanese clinical practice guidelines for DIC treatment have recommended the use of rhs-TM, while British clinical practice guidelines have not mentioned the use of rhs-TM. [23][24][25][26] In addition, developing nations tend to have lower diffusion speeds and lower maximum penetration levels of new drugs than do developed countries. 27 Therefore, further investigation of the use of rhs-TM in other countries is vital to confirm the impact of the increasing use of rhs-TM in patients with infectious disease-associated DIC.…”

Section: Discussionmentioning

confidence: 99%

Recent Change in Treatment of Disseminated Intravascular Coagulation in Japan

Murata

Okamoto

Mayumi

et al. 2015

Clin Appl Thromb Hemost

View full text Add to dashboard Cite

This study investigated the time trends and hospital factors affecting the use of drugs for infectious disease-associated disseminated intravascular coagulation (DIC) based on a national administrative database. A total of 14 324 patients with infectious disease-associated DIC were referred to 1041 hospitals from 2010 to 2012 in Japan. Patients' data were collected from the administrative database to determine time trends and hospital factors affecting the use of drugs for DIC. Three study periods were established, namely, the fiscal years 2010 (n ¼ 3308), 2011 (n ¼ 5403), and 2012 (n ¼ 5613). The use of antithrombin, heparin, protease inhibitors, and recombinant human soluble thrombomodulin (rhs-TM) for DIC was evaluated. The frequency of use of antithrombin, heparin, and protease inhibitors decreased while that of rhs-TM significantly increased from 2010 to 2012 in Japan (25.1% in 2010, 43.1% in 2011, and 56.8% in 2012; P < .001, respectively). Logistic regression showed that the study period was associated with the use of rhs-TM in patients with DIC. The odds ratio (OR) for 2011 was 2.34 (95% confidence interval [CI], 2.12-2.58; P < .001) whereas that for 2012 was 4.34 (95% CI, 3.94-4.79; P < .001). A large hospital size was the most significant factor associated with the use of rhs-TM in patients with DIC (OR, 3.14; 95% CI, 2.68-3.66; P < .001). The use of rhs-TM has dramatically increased. A large hospital size was significantly associated with the increased use of rhs-TM in patients with DIC from 2010 to 2012 in Japan.

show abstract

Diagnosis and treatment of disseminated intravascular coagulation: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET)

Cited by 123 publications

References 45 publications

A Randomized, Controlled, Multicenter Trial of the Effects of Antithrombin on Disseminated Intravascular Coagulation in Patients With Sepsis

A Randomized, Controlled, Multicenter Trial of the Effects of Antithrombin on Disseminated Intravascular Coagulation in Patients With Sepsis

How I treat disseminated intravascular coagulation

Recent Change in Treatment of Disseminated Intravascular Coagulation in Japan

Contact Info

Product

Resources

About